Berenberg Trims Sanofi Price Target on Mixed Data for COPD Drug
I'm PortAI, I can summarize articles.
Berenberg has reduced Sanofi's price target from 120 euros to 118 euros due to mixed late-stage results for its COPD drug, itepekimab. The analysts have removed the drug from their model and lowered the 2030 EPS estimate by 1%. Despite concerns about Sanofi's R&D profile, they maintain a buy rating, highlighting the company's attractive growth potential with a projected sales CAGR of 8% from 2024 to 2028, compared to the large pharma median of 5%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments